Liraglutide Switch from Sitagliptin in Type 2 Diabetes Patients Evaluated for Efficacy and Safety
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
Background
Type 2 Diabetes Mellitus (T2DM) management often requires combination therapy to achieve optimal glycaemic control. Dipeptidyl peptidase-4 (DPP-4) inhibitors like sitagliptin enhance endogenous incretin effects, while glucagon-like peptide-1 receptor (GLP-1R) agonists like liraglutide directly activate the GLP-1R, leading to more potent glucose-dependent insulin secretion and other metabolic benefits. Patients often fail to reach target HbA1c levels on initial therapies like metformin and DPP-4 inhibitors, necessitating treatment intensification. This study addresses the clinical question of whether switching from a DPP-4 inhibitor to a GLP-1R agonist offers superior efficacy and safety in this specific patient population.